Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 2/3 1

Status

Recruiting 3Active not recruiting 2Terminated 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 2NIH 1NETWORK 1

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Breast 4Gynecologic 1

Conditions

Breast Neoplasms 3Lymphatic Abnormalities 2Lymphangioma, Cystic 2Lymphangioma 2Vascular Malformations 1Triple Negative Breast Neoplasms 1Skin Diseases, Vascular 1Ovarian Neoplasms 1Neoplasm Metastasis 1Hyperglycemia 1Genetic Diseases, Inborn 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Arteriovenous Malformations 1

Interventions

Specimen Handling 427Magnetic Resonance Spectroscopy 338pembrolizumab 262Biopsy 230Carboplatin 216Cisplatin 180Cyclophosphamide 174Paclitaxel 148Nivolumab 136Gemcitabine 130Radiotherapy 125Dexamethasone 105Bevacizumab 103Radiation 97fludarabine 95Fluorouracil 93Doxorubicin 90Pemetrexed 88Docetaxel 85Rituximab 83durvalumab 82venetoclax 81Oxaliplatin 81Leucovorin 76atezolizumab 70Prednisone 66Lenalidomide 66Capecitabine 66Etoposide 64Vincristine 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Alpelisib × 30 days × Clear all
NCT05564377 2026-05-27

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05392608 2026-05-22

SEQUEL-Breast

Borstkanker Onderzoek Groep

Phase 2 Active not recruiting
130 enrolled
Breast

Breast Neoplasms, Genetic Diseases, Inborn

NCT05948943 2026-05-12

EPIK-L1

Novartis

Phase 2/3 Recruiting
232 enrolled

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

NCT04251533 2026-05-11

EPIK-B3

Novartis

Phase 3 Terminated
137 enrolled 21 charts
Breast

Triple Negative Breast Neoplasms

NCT05646862 2026-05-06

INAVO121

Hoffmann-La Roche

Phase 3 Active not recruiting
420 enrolled
Breast

Breast Neoplasms

NCT06083038 2026-05-06

Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib

HealthPartners Institute

Completed
8 enrolled
Breast

Breast Neoplasms, Hyperglycemia

NCT05983159 2026-05-05

TARGET-VM

Murdoch Childrens Research Institute

Phase 2 Recruiting
50 enrolled

Arteriovenous Malformations, Lymphangioma, Skin Diseases, Vascular, Lymphangioma, Cystic, Lymphatic Abnormalities, Vascular Malformations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡